Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Dylan Dupuis is an analyst at Roth MKM. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/23/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/19/2023 | CMMB | Buy Now | Chemomab Therapeutics | $1.26 | 455.34% | Dylan Dupuis61% | $7 → $7 | Reinstates | → Buy | Get Alert |
| 10/06/2023 | CMMB | Buy Now | Chemomab Therapeutics | $1.26 | 455.34% | Dylan Dupuis61% | → $7 | Initiates | → Buy | Get Alert |
| 09/21/2023 | IVA | Buy Now | Inventiva | $2.97 | 270.37% | Dylan Dupuis61% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | ASLN | Buy Now | ASLAN Pharma | — | — | Dylan Dupuis61% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | TERN | Buy Now | Terns Pharma | $3.42 | 572.51% | Dylan Dupuis61% | → $23 | Reiterates | → Buy | Get Alert |
| 06/30/2023 | TERN | Buy Now | Terns Pharma | $3.42 | 572.51% | Dylan Dupuis61% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | VKTX | Buy Now | Viking Therapeutics | $28.90 | 10.73% | Dylan Dupuis61% | → $32 | Assumes | → Buy | Get Alert |
| 05/31/2023 | ASLN | Buy Now | ASLAN Pharma | — | — | Dylan Dupuis61% | → $120 | Initiates | → Buy | Get Alert |
| 05/31/2023 | IVA | Buy Now | Inventiva | $2.97 | 270.37% | Dylan Dupuis61% | → $11 | Initiates | → Buy | Get Alert |
| 05/31/2023 | TERN | Buy Now | Terns Pharma | $3.42 | 572.51% | Dylan Dupuis61% | → $23 | Initiates | → Buy | Get Alert |
| 05/31/2023 | UBX | Buy Now | Unity Biotechnology | $1.76 | 468.18% | Dylan Dupuis61% | → $10 | Initiates | → Buy | Get Alert |
